Aldara (Imiquimod)

What is Aldara?

Aldara (imiquimod 5% cream) is a prescription topical medicine used to treat external genital and perianal warts caused by certain strains of the human papillomavirus (HPV). It is approved by the European Medicines Agency (EMA) and classified as an immune response modifier rather than a direct antiviral agent.

Unlike treatments that physically destroy wart tissue, Aldara works by engaging the body’s own immune system to target HPV-infected cells. This mechanism distinguishes it from other wart treatments such as podophyllotoxin (Condyline, Warticon) and cryotherapy.

How does Aldara work?

Imiquimod, the active ingredient in Aldara, acts as a toll-like receptor 7 (TLR7) agonist. When applied to wart tissue, it binds to immune cells in the skin and triggers a cascade of immune responses:

• Interferon production: Imiquimod stimulates the release of interferon-alpha and other cytokines, which activate the immune system’s antiviral response at the site of application.
• Cytokine cascade: The immune activation leads to local production of tumour necrosis factor-alpha (TNF-alpha) and interleukins, which promote immune cell infiltration into wart tissue.
• Cell-mediated immunity: T-lymphocytes are recruited to the treatment area, where they target and eliminate HPV-infected keratinocytes.
• Indirect antiviral effect: Because imiquimod acts on immune cells rather than directly on the virus, it does not kill HPV; instead, it helps the immune system clear infected tissue.

This immune-mediated mechanism explains why local skin reactions (redness, erosion, flaking) are both expected and indicative that the medicine is working.

Who is Aldara for?

Aldara is indicated for adults with external genital and perianal warts. It is not suitable for:

• Internal warts: Aldara is for external use only and should not be applied inside the vagina, urethra, or rectum.
• Children and adolescents: The safety and efficacy of imiquimod in patients under 18 years have not been established for this indication.
• Pregnant women: There is limited safety data for imiquimod in pregnancy. A doctor must carefully assess the risk-benefit balance.
• Patients with compromised immune systems: Imiquimod’s mechanism depends on an intact immune response; effectiveness may be reduced in significantly immunocompromised individuals.

A full medical assessment by a qualified independent doctor is required before any prescription is issued.

Dosage and application

Aldara 5% cream is applied three times per week (for example, Monday, Wednesday, Friday) before normal sleeping hours, typically for a period of 6 to 16 weeks.

Application instructions (as per EMA-approved guidance):

1. Wash the treatment area with mild soap and water and allow to dry.
2. Apply a thin layer of Aldara cream to the warts and rub in gently until absorbed.
3. Leave the cream on for 6 to 10 hours, then wash off with soap and water.
4. Do not cover the treated area with an occlusive dressing.
5. Avoid sexual contact while the cream is on the skin.

Aspect	Detail
Application frequency	3 times per week (non-consecutive days)
Maximum duration	16 weeks
Cream per application	Up to 250 mg (one sachet or a small pump dose)
Wash-off time	6–10 hours after application

Treatment should be discontinued if severe local skin reactions occur, and resumed when the reaction has subsided. A doctor should be consulted if warts worsen or do not improve.

Side effects

Aldara is associated with predictable local skin reactions, which reflect the immune activation at the treatment site.

Very common side effects (affecting more than 1 in 10 people)

• Redness (erythema) at the application site
• Flaking or peeling of the skin
• Itching
• Burning or stinging sensation

Common side effects (affecting 1 to 10 in 100 people)

• Erosion or ulceration at the application site
• Swelling or oedema
• Induration (hardening of skin)
• Scabbing

Less common but notable effects

• Flu-like symptoms (fatigue, headache, myalgia)
• Pigmentation changes at the treatment site (which may be persistent)
• Remote site skin reactions

Severe local reactions may require a treatment break. Patients should contact their doctor if they experience any reaction that concerns them.

Aldara vs alternative wart treatments

Several treatment options are available for external genital warts in Europe. The choice between them depends on wart characteristics, patient preference, and clinical assessment by an independent doctor.

Treatment	Active Ingredient	Mechanism	Application
Aldara	Imiquimod	Immune stimulation	3x/week cream, up to 16 weeks
Condyline	Podophyllotoxin	Antimitotic (cell death)	Twice daily, 3 days on/4 days off
Warticon	Podophyllotoxin	Antimitotic (cell death)	Twice daily, 3 days on/4 days off
Cryotherapy	Liquid nitrogen	Physical destruction	Clinic-based procedure

Aldara is generally preferred for larger or multiple wart areas where patient-applied treatment over several weeks is appropriate. Podophyllotoxin preparations may offer faster clearance of smaller lesions. All treatment decisions must be made by a qualified doctor.

How to access Aldara online in Europe

Aldara is a prescription-only medicine (POM) in all EU member states. It cannot legally be dispensed without a valid prescription from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicines, employ doctors, or sell medicines. Our platform connects patients with independent EU-registered doctors who can conduct confidential online health assessments.

The process:

1. Complete a health assessment: Answer structured questions about your health history, current symptoms, and medications. Your responses are reviewed by an independent doctor.
2. Doctor review: An independent EU-registered doctor reviews your assessment. If imiquimod is clinically appropriate, they may issue a prescription.
3. Pharmacy fulfilment: If a prescription is issued, it is sent to a licensed EU pharmacy partner, which dispenses and ships the medicine directly to you.

Important: Prescrivia does not guarantee that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals.

Important safety information

Do not use Aldara if you:

• Are allergic to imiquimod or any other ingredient in the cream
• Have open wounds or broken skin at the intended application site
• Have not been assessed by a doctor for the nature of your skin lesions

Tell your doctor before using Aldara if you:

• Are pregnant, planning to become pregnant, or breastfeeding
• Have a compromised immune system (including HIV infection or are taking immunosuppressant medicines)
• Have any inflammatory skin conditions in the treatment area
• Have previously used any other treatment for genital warts

Drug interactions: Imiquimod is applied topically and systemic drug interactions are not well documented; however, avoid use with other topical products on the same area simultaneously unless directed by a doctor.

Aldara does not treat the underlying HPV infection and does not prevent transmission to sexual partners. Barrier contraception (condoms) reduces but does not eliminate the risk of HPV transmission.

Sources

Medical information on this page is based on the following sources:

• European Medicines Agency (EMA). Aldara (imiquimod) — Summary of Product Characteristics. Available at: ema.europa.eu
• World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer — Fact sheet. who.int
• Beutner KR, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrobial Agents and Chemotherapy. 1998;42(4):789–794.

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.